Glycopyrronium Other names: Glycopyrronium bromide

Chemical formula: C₁₉H₂₈NO₃+  Molecular mass: 318.431 g/mol  PubChem compound: 9933193

Therapeutic indications

Glycopyrronium is indicated for:

Chronic obstructive pulmonary disease

Population group: only adults (18 years old or older)

Glycopyrronium bromide is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Severe sialorrhoea in patients with chronic neurological disorders

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Glycopyrronium is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Glaucoma

Glaucoma

Urinary retention

Retention of urine

History of intestinal obstruction, ulcerative colitis, paralytic ileus, pyloric stenosis and myasthenia gravis

at least one of
Intestinal obstruction
Colitis gravis
H/O: ulcerative colitis
Paralytic ileus
PS - Pyloric stenosis
Myasthenia gravis

Concomitant treatment with potassium chloride solid oral dose and anticholinergics

at least one of
Potassium chloride
Anticholinergics

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2021: TOVANOR BREEZHALER Inhalation powder, hard capsule
Summary of Product Characteristics (SPC) 2024: SIALANAR Oral solution
Structured Product Labeling (SPL/PLR) 2020: CUVPOSA Oral solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈